|
Report No. : |
316719 |
|
Report Date : |
13.04.2015 |
IDENTIFICATION DETAILS
|
Name : |
B Y B FARMACEUTICA LTDA. |
|
|
|
|
Registered Office : |
Avenida Parinacota 381 Of. Quilicura Santiago |
|
|
|
|
Country : |
Chile |
|
|
|
|
Date of Incorporation : |
25.07.2002 |
|
|
|
|
Legal Form : |
Limited Company |
|
|
|
|
Line of Business : |
Pharmaceutical Industry |
|
|
|
|
No. of Employee : |
15 |
RATING & COMMENTS
|
MIRA’s Rating : |
Ba |
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
Status : |
Satisfactory |
|
|
|
|
Payment Behaviour : |
No complaints |
|
|
|
|
Litigation : |
Clear |
NOTES :
Any query related to this report can be made
on e-mail : infodept@mirainform.com
while quoting report number, name and date.
ECGC Country Risk Classification List – December 31, 2014
|
Country Name |
Previous Rating (30.09.2014) |
Current Rating (31.12.2014) |
|
Chile |
A1 |
A1 |
|
Risk Category |
ECGC
Classification |
|
Insignificant |
A1 |
|
Low |
A2 |
|
Moderate |
B1 |
|
High |
B2 |
|
Very High |
C1 |
|
Restricted |
C2 |
|
Off-credit |
D |
CHILE ECONOMIC OVERVIEW
Chile has a market-oriented economy characterized by a high level of foreign trade and a reputation for strong financial institutions and sound policy that have given it the strongest sovereign bond rating in South America. Exports of goods and services account for approximately one-third of GDP, with commodities making up some three-quarters of total exports. Copper alone provides 19% of government revenue. From 2003 through 2013, real growth averaged almost 5% per year, despite the slight contraction in 2009 that resulted from the global financial crisis. Chile deepened its longstanding commitment to trade liberalization with the signing of a free trade agreement with the US, which took effect on 1 January 2004. Chile has 22 trade agreements covering 60 countries including agreements with the European Union, Mercosur, China, India, South Korea, and Mexico. Chile has joined the United States and nine other countries in negotiating the Trans-Pacific-Partnership trade agreement. The Chilean Government has generally followed a countercyclical fiscal policy, accumulating surpluses in sovereign wealth funds during periods of high copper prices and economic growth, and generally allowing deficit spending only during periods of low copper prices and growth. As of 31 December 2012, those sovereign wealth funds - kept mostly outside the country and separate from Central Bank reserves - amounted to more than $20.9 billion. Chile used these funds to finance fiscal stimulus packages during the 2009 economic downturn. In May 2010 Chile signed the OECD Convention, becoming the first South American country to join the OECD.
|
Source
: CIA |
Company
name and address
|
|
|
|
|
|
Legal Name: |
B Y B FARMACEUTICA LTDA. |
|
Trade Name: |
B Y B
FARMACEUTICA |
|
RUT: |
77787390-3 |
|
Date Created: |
24/06/1905 |
|
Date
Incorporated: |
25/07/2002 |
|
Legal Address: |
Avenida
Parinacota 381 Of. |
|
Operative
Address: |
Avenida
Parinacota 381 Of. |
|
Telephone: |
(56-2) 2739 2372 |
|
Fax: |
(56-2) 2739 2372 |
|
Legal Form: |
Limited Company |
|
Email: |
NA |
|
Registered in: |
Chile |
|
Website: |
No website |
|
Contact: |
Rodrigo Barrios |
|
Staff: |
15 |
|
Activity: |
Pharmaceutical Industry |
|
|
|
|
BANKS |
Banco Santander
Rio |
|
|
|
|
|
The company does
not make its banking data public. |
HISTORY
|
|
|
|
The company
started business in 2002 |
|
|
|
PRINCIPAL
ACTIVITY
|
|
|
|
The company is a
pharmaceutical products importer and distributor in Chile. |
|
Products/Services
description: |
FOOD SUPPLEMENT |
|
Brands: |
CICLOTEST |
|
Sales are: |
Wholesale |
|
Clients: |
Pharmacies |
|
Suppliers: |
Bal Pharma Ltd. |
|
Operations area:
|
National |
|
The company
imports from |
India and China |
|
The company
exports to |
No exports |
|
The subject
employs |
15 employees |
|
Payments: |
Regular |
|
|
|
LOCATION
|
|
|
Headquarters : |
Avenida
Parinacota 381 Of. |
|
Branches: |
The company does
not have branches |
|
Industry: |
Companies in
this industry manufacture and process pharmaceutical products. Demand for
pharmaceuticals is driven by the desire to cure illness and disease. The
profitability of individual companies depends on their ability to discover
and market new drugs. Large companies benefit from their economies of scale
in research, manufacturing, and marketing. Small companies can compete
effectively by specializing in drugs that target one or two specific ailments
and by partnering with larger drugmakers. Drugs are chemicals
with beneficial biological activity. Modern drug development is an outgrowth
of recent research into the specific causes of illness and disease, coupled
with advances in chemistry and industrial technology that allow scientists to
manufacture chemicals to improve these conditions. |
GROUP STRUCTURE AND SUBSIDIARY COMPANIES
|
|
|
Listed at the
stock exchange: |
NO |
|
Capital: |
NA |
|
Shareholders %: |
This is a
provate company. Despite our long search, we could not confirm major holders. |
|
Management: |
Rodrigo Barrios
Etcheverria, General Manager |
|
Related
Companies: |
No subsidiary
companies |
|
|
|
FINANCIAL
INFORMATION
|
|
|
|
This is a
private company which does not make its financial statements public. |
|
|
|
|
Revenue USD |
|
|
2013 |
2 300 000 |
|
|
|
|
Imports in US$ |
|
|
Year |
Total |
|
2013 |
US$ 1,195,180 |
|
2012 |
US$ 1,198,371 |
|
2011 |
US$ 357,481 |
|
2010 |
US$ 145,716 |
LEGAL
FILINGS
|
|
|
|
There are no
legal for the subject |
SUMMARY
|
|
|
|
ByB
Farmaceutica is a Chilean company dedicated to the import and wholesale of
pharmaceutical products. The company has 13
years of experience in the market with a small sized structure. It mainly
imports from China and India and distributes nationally. The company has
a low comercial profile. However, it is well established without negative. |
|
|
|
RISK
INFORMATION
|
|
|
DEBTS |
Controlled |
|
PAYMENTS |
Regular |
|
CASH FLOW |
Normal |
|
SUGGESTED CREDIT
LINE |
USD 50 000 |
|
STATUS |
Active |
|
|
|
|
ENTERVIEW |
|
|
NAME |
Jean |
|
POSITION |
Coordinator |
|
COMMENTS |
She confirmed address,
activity, brands and refused to confirm more data on the subject. |
FOREIGN EXCHANGE RATES
|
Currency |
Unit
|
Indian Rupees |
|
US Dollar |
1 |
Rs.62.37 |
|
|
1 |
Rs.91.60 |
|
Euro |
1 |
Rs.66.49 |
INFORMATION DETAILS
|
Analysis Done by
: |
KAR |
|
|
|
|
Report Prepared
by : |
ANK |
RATING EXPLANATIONS
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
>86 |
Aaa |
Possesses an extremely sound financial base with the strongest capability
for timely payment of interest and principal sums |
Unlimited |
|
71-85 |
Aa |
Possesses adequate working capital. No caution needed for credit
transaction. It has above average (strong) capability for payment of interest
and principal sums |
Large |
|
56-70 |
A |
Financial & operational base are regarded healthy. General
unfavourable factors will not cause fatal effect. Satisfactory capability for
payment of interest and principal sums |
Fairly Large |
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
26-40 |
B |
Capability to overcome financial difficulties seems comparatively
below average. |
Small |
|
11-25 |
Ca |
Adverse factors are apparent. Repayment of interest and principal sums
in default or expected to be in default upon maturity |
Limited with
full security |
|
<10 |
C |
Absolute credit risk exists. Caution needed to be exercised |
Credit not
recommended |
|
-- |
NB |
New Business |
-- |
This score serves as a reference to assess
SC’s credit risk and to set the amount of credit to be extended. It is calculated
from a composite of weighted scores obtained from each of the major sections of
this report. The assessed factors and their relative weights (as indicated
through %) are as follows:
Financial
condition (40%) Ownership
background (20%) Payment record
(10%)
Credit history
(10%) Market trend (10%) Operational size
(10%)
This report is issued at your request without any
risk and responsibility on the part of MIRA INFORM PRIVATE LIMITED (MIPL)
or its officials.